Antibiotic methods and compositions for bacteria infections

Patent metadata

Field	Value
Publication number	US-9861619-B2
Application number	US-201314439850-A
Country	US
Kind code	B2
Filing date	Nov 1, 2013
Priority date	Nov 1, 2012
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.

First claim

The invention claimed is:

1. A method for inhibiting a staphylococcus infection comprising administering to a subject having a staphylococcus infection or at risk of a staphylococcus infection:
(a) oxacillin, and;
(b) an antibiotic potentiator, wherein the antibiotic potentiator is clomifene, gossypol, menadione, pyrvinium, or a prodrug or salt thereof.

2. The method of claim 1 , wherein the subject has been tested for a staphylococcus infection.

3. The method of claim 1 , wherein the staphylococcus infection is Staphylococcus aureus.

4. The method of claim 1 , wherein the staphylococcus infection is methicillin resistant Staphylococcus aureus (MRSA).

5. The method of claim 1 , wherein the subject has or is at risk for native valve endocarditis or prosthetic valve endocarditis.

6. The method of claim 5 , wherein the subject is administered about 2-3 g of oxacillin intravenously every 4 to 6 hours.

7. The method of claim 1 , wherein the subject has or is at risk for joint infection, meningitis, osteomyelitis, pneumonia, septicemia, sinusitis, or skin or soft tissue infection.

8. The method of claim 1 , further comprising administering a second antibiotic.

9. The method of claim 8 , wherein the second antibiotic is gentamicin or rifampin.

10. The method of claim 1 , wherein the subject is a pediatric patient.

11. The method of claim 1 , whereby administration to a subject is oral, sublingual, sublabial, gastrointestinal, rectal, epicutaneous (topical), intradermal, subcutaneous, nasal, intravenous, intraarterial, intramuscular, intracardiac, intraosseous, intrathecal, intraperitoneal, intravesical, intravitreal, intracavernous, intravaginal, intrauterine, epidural, intracerebral and/or intracerebroventricular.

12. The method of claim 1 , wherein administration is topical, enteral, or parenteral.

13. The method of claim 1 , wherein administration is by application onto the skin, inhalation, an enema, eye drops, ear drops, absorption across mucosal membranes, the mouth, a gastric feeding tube, a duodenal feeding tube, a suppository, an injection into a vein, an injection into an artery, an injection into the bone marrow, an injection into muscle tissue, an injection into the brain, an injection into the cerebral ventricular system or an injection under the skin.

14. The method of claim 1 , wherein the antibiotic and the antibiotic potentiator are administered in the same composition.

15. The method of claim 1 , wherein the antibiotic potentiator is selected from clomiphene, gossypol, and pyrvinium.

Assignees

• Univ Chicago

Inventors

• Daum Robert S
• Boyle-Vavra Susan

Classifications

• A61K31/138

  Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/165

  having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K31/381

  having five-membered rings · CPC title